

### **Abstract of the Disclosure**

“Pharmacological enhancement and manufacturing method of the antiviral compound” can be categorized into the combined patent of the pharmacological activity as well as method of isolating and purifying the naturing material. Our product adopts 9 medicinal material which are processed strictly. The stable and high quality is ensured by the WLD resin adsorption and gas chromatography.

The antiviral prevention and treatment is the most urgent but unsolved problem before the American doctors. The antiviral compound has an unexpected effect on a broad spectrum of viruses including RSV, Adenovirus type 3, Influenza A1 and A3. The antiviral effect on mouse Influenza A1 is very obvious. The definite efficacy in the treatment of acute pharyngitis and tonsillitis have been proved by the clinical trial which showed the total effective rate in the above two disease were 92.3% and 87.5% respectively.

## Abstract of the Disclosure

(attached table 1)


Radix Scutellariae	12%
Fructus Forsythiae	20%
Herbs Schizone Petae	15%
Flos Chrysanthemi	15%
Radix Scrophulariae	15%
Cornu Bubaci	10%
Radixet Rhizoma Rhei	4.5%
Spina Gleditsiae	4.5%
Widus Vespae	4%
Total	100%

(attached table 2)

1	Radix Scutellariae	2	Fructus Forsythiae	3	Herbs Schizone Petae
	Labiatae Scutellaria baicalensis Georgi(root)		Oleaceae Forsythia Suspensa(Thumb) VahL. 的 (fruit)		Labiatae Schizonepeta tenuifolia Brig (falling branches and leaves)
4	Flos Chrysanthemi	5	Radix Scrophulariae	6	Cornu Bubaci
	Compositae Chrysanthemum morifolium Ramat(capitulum)		Scrophulariaceae Scrophularia ningpoensis HemsL.(root)		Bovidae Bubalus bubalis Linnaeus(horn)
7	Radixet Rhizoma Rhei	8	Spina Gleditsiae	9	Widus Vespae
	Polygonaceae Rheum PalmatumL.(root and stem)		Leguminosae Gleditsia Sineusis Lam(thorns)		Vespidae Polistes Olivaceous(DeGeer) (adult)

## Abstract of the Disclosure

(attached table 3)



## Abstract of the Disclosure

(attached table 4)

Name		RSV	Adenovirus type 3	A1 (Influenza Virus A1)
Antiviral compound	Toxic-free Viral Load (including the drug dosage mg/ml)	1:64(31.25mg/ml)	1:64(31.25mg/ml)	2(4000mg/ml)
	Maximum Dilution Ratio (including the drug dosage mg/ml)	1:256(7.81mg/ml)	1:512(3.90mg/ml)	1:16(125.00mg/ml )
	Inhibition Index			

(attached table 5)

Name	RSV	Influenza Virus A1	Influenza Virus A3
Antiviral compound	Toxic-free Viral Load (including the drug dosage mg/ml)	1(2000mg/ml)	1(2000mg/ml)
	Maximum Dilution Ratio (including the drug dosage mg/ml)	1:2(1000mg/ml)	1:4(500mg/ml)
	Inhibition Index		

(attached table 6)

Group	Dosage (g/kg/d)	LW:BW (X)	Inhibition rate (%)	P value
Viral control	-	10.49±0.45		
Normal control	-	7.86±0.32		
Antiviral Compound			12.01	<0.05
Antiviral Compound	6.875(12.5)	8.09±0.17	22.87	<0.001
Drug dosage( g/kg/d)	13.75(25.0)	7.98(0.23)	23.92	<0.001

## Abstract of the Disclosure

(attached table 7)

Disease	Group	n	Cured		Apparent effect		Effect		Invalid		Total apparent effect rate		Total effect rate	
			Cases	%	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
Acute pharyngitis	Treatment group	182	79	(43.4)	63	(34.6)	26	(14.3)	14	(7.7)	142	(78.0)	168	(92.3)

Rank test:  $U=3.24$   $P<0.01$

(attached table 8)

Disease	Group	n	Cured		Apparent effect		Effect		Invalid		Total apparent effect rate		Total effect rate	
			Cases	%	Cases	%	Cases	%	Cases	%	Cases	%	Cases	%
Acute tonsillitis	Treatment group	120	56	(46.7)	33	(27.5)	16	(13.3)	15	(12.5)	89	(74.2)	105	(87.5)

Rank test:  $U=3.65$   $P<0.001$

(attached table 9)

Group		Pharyngalgia	Pharyngalgia with swallowing pain	pharyngalgia involved with ear	Pharyngeal congestion	Retropharyngeal lymphoproliferation	uvular congestion	Parapharyngeal swellingness and redness
Treatment group	Before treatment	53	106	23	130	129	32	92
	After treatment	5	3	5	29	27	5	8
	Effective rate	90.6%	97.2%	78.3%	77.7%	79.1%	84.4%	91.3%

## Abstract of the Disclosure

(attached table 10)

Group		Pharyngalgia	Pharyngalgia with swallowing pain	pharyngalgia involved with ear	Tonsil congestion	Swollen tonsil	Purulent secretion on the tonsil
Treatment group	Before treatment	32	67	21	84	77	31
	After treatment	3	9	6	25	14	5
	Effective rate	90.6%	86.6%	71.4%	70.2%	81.8%	83.9%

(attached table 11)

Group	Severity	n	Cured		Apparent effect		Effect		Invalid		Total effective rate	Total apparent effect rate
			Cases	%	Cases	%	Cases	%	Cases	%	%	%
Treatment group	Mild	47	32	(68.1)	10	(21.3)	5	(10.6)	0	(0)	100	89.4
	Medium	110	45	(40.9)	43	(39.1)	15	(13.6)	7	(6.4)	93.6	80.0
	Severe	25	2	(8.0)	10	(40.0)	6	(24.0)	7	(28.0)	72.0	48.0

(attached table 12)

Group	Severity	n	Cured		Apparent effect		Effect		Invalid		Total effective rate	Total apparent effect rate
			Cases	%	Cases	%	Cases	%	Cases	%	%	%
Treatment group	Mild	28	22	(78.6)	6	(21.4)	0	(0)	0	(0)	100	100
	Medium	67	25	(37.4)	22	(32.8)	10	(14.9)	10	(14.9)	85.1	70.2
	Severe	25	9	(36.0)	5	(20.0)	6	(24.0)	5	(20.0)	80.0	56.0

## Abstract of the Disclosure

---

(attached table 13)

Disease	Group	Cases (effect)	X±SD
Acute pharyngitis	Treatment group	168	1.39±0.66

(attached table 14)

Disease	Group	Cases (effect)	X±SD
Acute tonsillitis	Treatment group	105	1.78±0.90

(attached table 15)

Group	n	Efficacy	One day	Two days
Treatment group	79	Cured	48	31
	63	Apparent effect	23	40
	26	Effect	10	16
	14	Invalid	6	8

(attached table 16)


Group	n	Efficacy	One day	Two days	Three days
Treatment group	56	Cured	17	20	19
	33	Apparent effect	7	18	8
	16	Effect	4	7	5
	15	Invalid	4	4	7




## Abstract of the Disclosure

**BEST AVAILABLE COPY**

(attached table 17)




**Fig 1: Viral control**




**Fig 2. Antiviral compound group**





**Fig 3. Viral control**



**Fig 4. Antiviral compound group**